Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes.
'Arrowhead's two clinical stage RNAi-based obesity programs, ARO-ALK7 and ARO-INHBE, intervene in a known pathway that signals the body to store fat in adipose tissue. Both programs have strong genetic validation and promising results in preclinical studies, which suggest that silencing the respective genes may lead to reduced body weight and potentially preserve lean muscle mass resulting in improved body composition,' said James Hamilton, M.D., Chief Medical Officer and Head of R&D. 'This ongoing Phase 1/2a clinical study will evaluate single and multiple ascending doses of ARO-ALK7 as monotherapy in otherwise healthy obese volunteers as well as multiple doses in obese patients with or without type 2 diabetes in combination with incretin therapy.'
About ARO-ALK7
ARO-ALK7 is designed to silence adipocyte expression of the ACVR1C gene to reduce production of Activin receptor-like kinase 7 (ALK7), which acts as a receptor in a pathway that regulates energy homeostasis in adipose tissue. In large genetic datasets, reduced ACVR1C expression has been associated with healthier adipose distribution and reduced risk of obesity-related metabolic complications. In preclinical animal studies, ALK7 silencing in adipose tissue led to reduced body weight and fat mass with preservation of lean muscle. Treatment with investigational ARO-ALK7 has the potential to reduce visceral adiposity and improve lipid and glycemic parameters.
About the AROALK7-1001 Phase 1/2 Study
AROALK7-1001 ( NCT06937203 ) is a Phase 1/2a first-in-human dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-ALK7 in up to 90 adult volunteers with obesity. Part 1 of the study is designed to assess single and multiple doses of ARO-ALK7 monotherapy, and Part 2 of the study is designed to assess ARO-ALK7 in combination with tirzepatide, a subcutaneously administered GLP-1/GIP receptor co-agonist that has been approved in the United States and the European Union for management type 2 diabetes mellitus since 2022 and weight management since 2023/2024 respectively.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250602644854/en/
CONTACT: Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
[email protected]:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
[email protected]:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
[email protected]
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH DIABETES GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Arrowhead Pharmaceuticals, Inc.
Copyright Business Wire 2025.
PUB: 06/02/2025 07:30 AM/DISC: 06/02/2025 07:28 AM
http://www.businesswire.com/news/home/20250602644854/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Evercore Highlights Amazon (AMZN) Grocery Strategy and Prime Stickiness
Inc. (NASDAQ:AMZN) ranks among the . Evercore ISI highlighted Inc. (NASDAQ:AMZN)'s strategic actions in the grocery industry on August 13, reaffirming its Outperform rating and $280 price target on the company. The firm noted that by strengthening customer engagement through a high-frequency purchase category, Amazon's tighter integration of groceries into the Prime ecosystem raises customer lifetime value and stickiness. Amazon's $25 free delivery threshold, according to Evercore ISI, puts pressure on rivals like Walmart and Instacart to lower their prices. The approach is in line with Amazon's previously declared $4 billion commitment to use the country's current logistics infrastructure to extend its same-day and next-day delivery network to over 4,000 smaller and rural U.S. communities by 2026. According to Evercore's 13th Annual Amazon Survey, Prime Same-Day delivery multiplies the frequency of purchases, the expansion of categories, and the total amount spent by customers on Inc. (NASDAQ:AMZN). The firm refers to this as 'Shipping Elasticity', which suggests that faster shipping results in more frequent and larger purchases. Inc. (NASDAQ:AMZN), is an American multinational technology company that offers a wide range of commercial interests that include digital streaming, online advertising, e-commerce, cloud computing through Amazon Web Services (AWS), and artificial intelligence. While we acknowledge the potential of AMZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMZN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
13 minutes ago
- Yahoo
KeyBanc Raises Dycom Industries (DY) Price Target to $295 on Telecom Growth
Dycom Industries, Inc. (NYSE:DY) is one of the best Russell 2000 stocks to buy now. On July 16, KeyBanc Capital Markets increased its price target for Dycom stock to $295, up from $255. The firm maintained its 'Overweight' rating on Dycom's shares, citing the company's strong sector positioning and the expectation that telecom infrastructure investments will remain high in the years to come. Photo by Scott Blake on Unsplash Specifically, KeyBanc highlighted Dycom's position at the start of a multi-year telecom investment expansion. Dycom, the analysts stated, has made robust private investments in fiber. Add to that the ongoing federal and state-funded rural broadband programs, as well as aggressive data center-led fiber builds. KeyBanc expects these initiatives to drive elevated spending in the industry for several years. The analysts also noted Dycom's national reach and scale in wireline construction. They stated that this fact gives the company an advantage in competing for contracts and capturing incremental growth opportunities. In that regard, KeyBanc noted that Dycom, as a 'telecom pure-play trading at approximately 11.3x FY27 estimates,' does not have its longer-than-usual growth cycle fully reflected in its current valuation. Dycom Industries, Inc. (NYSE:DY) is a specialty contracting company. It provides engineering, construction, maintenance, and installation services for telecommunications and utility infrastructure. The company operates across the United States, serving major telecommunications providers, cable operators, and utility companies through a network of field offices staffed by over 15,000 employees. While we acknowledge the potential of DY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Energy Stocks to Buy For the Long Term and Top 10 Industrial Stocks to Buy Amid Easing Tariff Uncertainties. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
US budget deficit forecast $1 trillion higher over next decade, watchdog says
By David Lawder WASHINGTON (Reuters) -U.S. federal budget deficits will be nearly $1 trillion higher over the next decade than projected in January by the Congressional Budget Office as a result of tax and spending legislation and tariffs, a budget watchdog said on Wednesday. The Committee for a Responsible Federal Budget's latest forecasts show a cumulative deficit of $22.7 trillion from fiscal 2026 to 2035, compared to the CBO's January forecast of $21.8 trillion, which was based on laws and policies that were in place before U.S. President Donald Trump took office in January. The CBO, Congress' non-partisan budget referee agency, said on Monday that it will not issue its customary mid-year budget update this year and will issue its next 10-year budget and economic outlook in early 2026, offering no explanation for the move. The CRFB, which advocates for deficit reduction, projected a $1.7 trillion deficit in fiscal 2025 or 5.6% of GDP, down slightly from $1.83 trillion in 2024 and the CBO's 2025 projection of $1.87 trillion in January. But it said deficits steadily rise over the decade, reaching $2.6 trillion or 5.9% of GDP by 2035. The new CRFB estimates include the budget effects of the One Big Beautiful Bill Act tax and spending bill, as well as Trump's tariffs that are currently in place. But like CBO, they do not include the dynamic economic effects on growth from these changes, a forecasting rule that has drawn criticism from the Trump administration. The group projects the tax cut and spending bill to increase deficits, including interest, by $4.6 trillion through 2035, adding another year to the CBO's $4.1 trillion cost estimate through 2034. But CRFB estimates that this will be offset by $3.4 trillion worth of extra import duty revenue over the next decade due to Trump's new tariffs that are currently in place. New rules restricting eligibility for health insurance subsidies will reduce deficits by another $100 billion through 2035, and Congress' rescission of prior funding to foreign aid, public broadcasting and other programs would save another $100 billion if sustained over a decade, CRFB said. Net interest payments on the national debt will total $14 trillion over the decade, CRFB projected, rising from nearly $1 trillion or 3.2% of GDP in 2025 to $1.8 trillion or 4.1% of GDP in 2035. TARIFF CHALLENGE The forecasts are based on legislative and tariff changes since January but keep CBO's economic forecasts unchanged. Under an alternative scenario forecast by CRFB, the budget picture looks far worse, boosting deficits nearly $7 trillion higher than the CBO baseline. This scenario would see a significant part of Trump's tariffs canceled if the Court of International Trade's ruling against many of Trump's new tariffs is upheld, cutting $2.4 trillion from revenues over a decade. The alternative scenario also assumes extension of a number of temporary tax cuts in the One Big Beautiful Bill Act, including tax breaks on overtime, tips, Social Security income and car loan interest, higher state and local tax deduction allowances and full expensing of factory investments, adding $1.7 trillion to deficits over 10 years. CRFB's alternative scenario also ditches the CBO's projection of a decline in 10-year U.S. Treasury yields over the decade to about 3.8%. If that interest rate stays at the current level of about 4.3%, interest costs would grow by about $1.6 trillion through 2035, CRFB said. The total 2035 debt-to-GDP ratio would grow from 118% in the CBO January baseline to 120% under the CRFB's projected baseline scenario and 134% under the CRFB's alternative scenario. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
